Oxular Ltd raises US$37m
British Oxular Ltd has raised $37m in a financing round led by Forbion Parners and co-financed by IP Group, NeoMed, and V-Bio Ventures to push its pipeline.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
EU life science PPPs face less budget in Horizon Europe
The European Commission is set to fund ten "European Partnerships" partnered with different industries with €10bn.
MosaMeat BV closes US$85m Series B financing
Cultured meat producer MosaMeat BV has announced the third and final closing of its Series B round raising US$85m.
Knowledge Gain Through High Parallel Bioprocess Setups
DASbox® Mini Bioreactor System: In the Quality by Design (QbD) and Process Analytical Technology (PAT) era, the generation and validation of a large amount of data have become standard. Parallel bioreactor control systems offer the possibility to test and optimize different process parameters at the same time, thus saving time and resources.
Biomarker identifies high-risk COVID-19 patients
Austrian researchers have found that a lack of activation of the NK receptor is highly associated with severe COVID-19 disease courses.
MaxiVAX and Minaris Regenerative Medicine ink contract
Swiss cancer vaccine specialist MaxiVAX SA has hired Minaris Regenerative Medicine GmbH to produce its cell therapy MVX-ONCO-2.
EU orders additional COVID-19 vaccine doses
Pfizer Inc. and BioNTech SE have signed an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the EU.
Novel strategy targets chronic liver diseases
A resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells.
Cellectis and Cytovia in US$760m licence deal
Cell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
Higher omega-3 level apparently protects from dying from COVID-19
The association of a low HS-Omega-3 Index® and mortality from COVID-19 is analyzed in a comprehensive study with Munich hospital.